Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma
N/A
18 Years
70 Years
18 Years
70 Years
Not Enrolling
Both
Lymphoma
Both
Lymphoma
Trial Information
Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma
Patients are randomized to receive dose-dense CEOP/IMVP-Dexa chemotherapy or standard
3-weekly CHOP.
Inclusion Criteria:
- 18 and 70 years of age
- Centrally reviewed, histologically proven diffuse large B-cell, anaplastic
large-cell, or peripheral T-cell unspecified
- Measurable disease
- All stages
Exclusion Criteria:
- Lymphoblastic or Burkitt histology
- CNS-disease
- HIV-positive
- pregnant or lactating women
- Pretreatment
- Other malignancy
- Concomitant diseases that forbid chemotherapy
Type of Study:
Expanded Access
Study Design:
N/A
Authority:
Austria: Federal Ministry for Health and Women
Study ID:
NHL-5
NCT ID:
NCT00517894
Start Date:
Completion Date:
Related Keywords:
- Lymphoma
- lymphoma
- aggressive
- chemotherapy
- dose-dense
- Aggression
- Lymphoma
- Lymphoma, Non-Hodgkin
Name | Location |
|---|
